ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
L

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 Bispecific Checkpoint Inhibitor, as Monotherapy With Advanced RCC: Preliminary Results From the FTIH Trial

By ASCO 2022 Conference Coverage FEATURING Laurence Albiges
By ASCO 2022 Conference Coverage FEATURING Laurence Albiges
130 views
June 30, 2022
0 Comments
Login to view comments. Click here to Login
GU
21:32
ASCO 2022 Conference Coverage

ASCO 2022 Bladder Cancer Highlights

Feat. G. Sonpavde
04:42
ASCO 2022 Conference Coverage

ASCO 2022 on Olaparib + Abiraterone as 1L Therapy for mCRPC: Pharmac…

Feat. A. Armstrong
06:04
ASCO 2022 Conference Coverage

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA…

Feat. L. Albiges
05:15
ASCO 2022 Conference Coverage

ASCO 2022 on the Clinical Outcomes & Safety of Enzalutamide + AD…

Feat. R. Szmulewitz
04:00
ASCO 2022 Conference Coverage

ASCO 2022 CHAARTED Trial: Eight-Year Survival Rates by Baseline Prog…

Feat. A. Tripathi
03:11
ASCO 2022 Conference Coverage

ASCO 2022 Defining "Platinum-Ineligible" Pts With Metastat…

Feat. S. Gupta
03:44
ASCO 2022 Conference Coverage

ASCO 2022 MAIN-CAV: Phase III Randomized Trial of Maintenance Caboza…

Feat. S. Gupta
20:21
ASCO 2022 Conference Coverage

ASCO 2022 Highlights From Educational Sessions and Updates in Bladde…

Feat. P. Grivas
30:41
ASCO 2022 Conference Coverage

ASCO 2022 Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for C…

Feat. P. Kuo
01:22
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Real-World Treatment Patterns and Clinic…

Feat. G. Sonpavde
09:17
ASCO 2022 Conference Coverage

ASCO 2022 Real-World Treatment Patterns and Clinical Outcomes With 1…

Feat. G. Sonpavde
09:23
ASCO 2022 Conference Coverage

ASCO 2022 on Randomized Phase II Trial of Neoadjuvant ADT + Abirater…

Feat. D. Bastos
08:05
ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder …

Feat. G. Iyer
05:47
ASCO 2022 Conference Coverage

ASCO 2022 Maturation of Overall Survival in TIVO-3 With Long-Term Fo…

Feat. B. Rini